“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Christopher R. Fenimore net worth and biography

Christopher Fenimore Biography and Net Worth

VP of Regeneron Pharmaceuticals

Chris Fenimore joined Regeneron in 2003 and, as the current Head of Accounting and Controller, has global responsibility for SEC reporting, accounting and accounting operations, and internal control over financial reporting, administration of financial systems, accounts payable and payroll. Prior to his current role, he served as Regeneron’s Vice President of Financial Planning, and prior to joining Regeneron, he was Vice President of Finance at Mojave Therapeutics, Inc. He has prior experience in healthcare industry-focused venture capital and investment banking roles, as well as serving as an audit senior at KPMG. Mr. Fenimore holds an MA in Biotechnology from Columbia University, an MBA in Professional Accounting from Rutgers Business School and a BA in Economics from Rutgers University. Mr. Fenimore is a Certified Public Accountant in the State of New York.

What is Christopher R. Fenimore's net worth?: The estimated net worth of Christopher R. Fenimore is at least $11.30 million as of August 28th, 2024. Mr. Fenimore owns 15,305 shares of Regeneron Pharmaceuticals stock worth more than $11,295,090 as of November 23rd. This net worth evaluation does not reflect any other investments that Mr. Fenimore may own. Learn More about Christopher R. Fenimore's net worth.
How old is Christopher R. Fenimore?: Mr. Fenimore is currently 53 years old. There are 5 older executives and no younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals is Dr. Leonard S. Schleifer M.D., Ph.D., Co-Founder, President, CEO & Co-Chairman, who is 71 years old. Learn More on Christopher R. Fenimore's age.
How do I contact Christopher R. Fenimore?: The corporate mailing address for Mr. Fenimore and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Christopher R. Fenimore's contact information.
Has Christopher R. Fenimore been buying or selling shares of Regeneron Pharmaceuticals?: Christopher R. Fenimore has not been actively trading shares of Regeneron Pharmaceuticals during the last ninety days. Most recently, Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a transaction totalling $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at $18,447,575.65. Learn More on Christopher R. Fenimore's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 28 times. They sold a total of 108,095 shares worth more than $105,638,222.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Christopher R. Fenimore Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/28/2024	Sell	5,680	$1,205.33	$6,846,274.40	15,305
12/27/2023	Sell	2,448	$856.71	$2,097,226.08	14,372
12/21/2023	Sell	1,680	$844.01	$1,417,936.80	17,070
3/23/2023	Sell	2,192	$806.47	$1,767,782.24	18,409
10/5/2022	Sell	1,844	$749.00	$1,381,156.00	16,425
10/3/2022	Sell	3,346	$724.00	$2,422,504.00	18,269
7/21/2020	Sell	3,709	$642.04	$2,381,326.36	25,277
6/16/2020	Sell	3,556	$590.89	$2,101,204.84	20,323
4/1/2020	Sell	1,200	$488.41	$586,092.00	14,297
12/13/2019	Sell	1,682	$376.14	$632,667.48	9,697
12/20/2018	Sell	1,848	$358.97	$663,376.56	9,871

Christopher R. Fenimore Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $738.00

$737.63

$751.40

50 Day Range

MA: $945.07

$738.00

$1,153.08

2 Week Range

Now: $738.00

$735.95

$1,211.20

Volume

1,029,423 shs

Average Volume

539,322 shs

Market Capitalization

$81.10 billion

P/E Ratio

18.26

Dividend Yield

N/A

Beta

0.15

“Fed Proof” Your Bank Account with THESE 4 Simple Steps

From Weiss Ratings | Ad